This stock needs something stronger than shock treatment to rerate higher again. In the penalty box with no end in sight. Here are Consensus expectations for the quarter and forward guidance:
In Need of a Lobotomy: Axon Consensus Expectations into This Afternoon's Print
Consensus Estimates + Valuation Context
